A drug’s ability to reach the market is essential; however, pharmaceutical manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. Payers have displayed a need for a more humanistic approach; therefore, an effective engagement strategy for healthcare decision-makers is necessary to improve payer satisfaction and retention.
Read the whitepaper to learn more about stakeholders’ engagement needs based on a survey conducted by ICON’s Market Access team. Discover insights on: